Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
Safety study of SPARC1104
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
375
Subjects who exited study CLR\_09\_21
Subjects who received prior treatment regimen I
Subjects who received no prior treatment regimen
Number of Subjects With Adverse Events
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SPARC site 4
Gilbert, Arizona, United States
SPARC Site 34
Phoenix, Arizona, United States
SPARC Site 1
Tucson, Arizona, United States
SPARC Site 30
Costa Mesa, California, United States
SPARC Site 14
Newport Beach, California, United States
SPARC Site 32
Basalt, Colorado, United States
SPARC Site 5
Denver, Colorado, United States
SPARC Site 7
Derby, Connecticut, United States
SPARC site 47
Hartford, Connecticut, United States
SPARC Site 8
New London, Connecticut, United States
...and 41 more locations